Advertisement

Heart Failure Reviews

, Volume 24, Issue 1, pp 91–100 | Cite as

Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology

  • Peggy M. KostakouEmail author
  • Nikos T. Kouris
  • Vassilios S. Kostopoulos
  • Dimitrios S. Damaskos
  • Christoforos D. Olympios
Article
  • 519 Downloads

Abstract

Cardio-oncology is a new field of interest in cardiology that focuses on the detection, monitoring, and treatment of cardiovascular disease occurring as a side effect of chemotherapy and radiotherapy. Both cancer treatment modalities can cause cardiac dysfunction, a major cause of morbidity and mortality in the oncologic population. It is necessary to periodically monitor cancer patients under treatment, especially those receiving anthracyclines and trastuzumab (monoclonal antibody), using mainly 3D echocardiography to calculate left ventricular ejection fraction and to estimate myocardial deformation. Additionally, measuring various biomarkers, such as natriuretic peptides, could facilitate early identification and appropriate response to potential cardiotoxicity. In this regard, cardiological assessment before starting cancer treatment is essential and should be continued throughout, since cardiac dysfunction can occur at any time, even several years after therapy onset. High-risk individuals, in particular, should receive a detailed management plan designed in collaboration between an oncology and a cardiology specialist. If heart failure develops, even in the absence of overt clinical symptoms, standard heart treatment is to be followed and causal agent discontinued if possible. One important question is whether and when to stop cardiac medication in case of heart dysfunction reversal, after completion of cancer treatment. Further cardio-oncology evolution can lead to a deeper understanding of the adverse mechanisms and effects causing heart failure, as well as the development of personalized treatment regimens in order to limit cardiotoxicity.

Keywords

Cardiotoxicity Cancer Heart failure Echocardiography Strain 

Abbreviations

ACE

Angiotensin-converting enzyme

GLS

Global longitudinal strain

HF

Heart failure

LV

Left ventricular

LVEF

Left ventricular ejection fraction

MRI

Magnetic resonance imaging

VEGF

Vascular endothelial growth factors

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Manrique CR, Park M, Tiwari N, Plana JC, Garcia MJ (2017) Diagnostic strategies for early recognition of Cancer therapeutics-related cardiac dysfunction. Clin Med Insights Cardiol 11:1179546817697983CrossRefGoogle Scholar
  2. 2.
    Armstrong GT, Oeffinger KC, Chen Y, Kawashima T, Yasui Y, Leisenring W, Stovall M, Chow EJ, Sklar CA, Mulrooney DA, Mertens AC, Border W, Durand JB, Robison LL, Meacham LR (2013) Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 31:3673–3680CrossRefGoogle Scholar
  3. 3.
    Lenihan DJ, Cardinale DM (2012) Late cardiac effects of cancer treatment. J Clin Oncol 30:3657–3664CrossRefGoogle Scholar
  4. 4.
    Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, ESC Scientific Document Group (2016) ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology. Eur Heart J 37:2768–2801CrossRefGoogle Scholar
  5. 5.
    Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mayer EL, Moslehi J, Oeffinger K, Ray K, Ruddy K, Lenihan D (2017) Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 35:893–911CrossRefGoogle Scholar
  6. 6.
    Tamargo J, Caballero R, Delpón E (2015) Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf 38:129–152CrossRefGoogle Scholar
  7. 7.
    Farmakis D, Parissis J, Filippatos G (2014) Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol 63:945–953CrossRefGoogle Scholar
  8. 8.
    Conen D, Wong JA, Sandhu RK, Cook NR, Lee IM, Buring JE, Albert CM (2016) Risk of malignant cancer among women with new-onset atrial fibrillation. JAMA Cardiol 1:389–396.CrossRefGoogle Scholar
  9. 9.
    Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, Chung MK (2003) Inflammation as a risk factor for atrial fibrillation. Circulation 108:3006–3010CrossRefGoogle Scholar
  10. 10.
    Viganego F, Singh R, Fradley MG (2016) Arrhythmias and other electrophysiology issues in cancer patients receiving chemotherapy or radiation. Curr Cardiol Rep 18:52CrossRefGoogle Scholar
  11. 11.
    Viskin S, Rosovski U, Sands AJ, Chen E, Kistler PM, Kalman JM, Rodriguez Chavez L, Iturralde Torres P, Cruz FFE, Centurión OA, Fujiki A, Maury P, Chen X, Krahn AD, Roithinger F, Zhang L, Vincent GM, Zeltser D (2005) Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Heart Rhythm 2:569–574CrossRefGoogle Scholar
  12. 12.
    Rautaharju PM, Surawicz B, Gettes LS, Bailey JJ, Childers R, Deal BJ, Gorgels A, Hancock EW, Josephson M, Kligfield P, Kors JA, Macfarlane P, Mason JW, Mirvis DM, Okin P, Pahlm O, van Herpen G, Wagner GS, Wellens H, American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; American College of Cardiology Foundation; Heart Rhythm Society (2009) AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association electrocardiography and arrhythmias. Circulation 119:241–250CrossRefGoogle Scholar
  13. 13.
    Naing A, Veasey-Rodrigues H, Hong DS, Fu S, Falchook GS, Wheler JJ, Tsimberidou AM, Wen S, Fessahaye SN, Golden EC, Aaron J, Ewer MS, Kurzrock R (2012) Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol 23:2960–2963CrossRefGoogle Scholar
  14. 14.
    Epstein AE, JP DM, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Tracy CM, Epstein AE, Darbar D, Di Marco JP, Dunbar SB, Estes NA 3rd, Ferguson TB Jr, Hammill SC, Karasik PE, Link MS, Marine JE, Schoenfeld MH, Shanker AJ, Silka MJ, Stevenson LW, Stevenson WG, Varosy PD, American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Heart Rhythm Society (2013) 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guide. J Am Coll Cardiol 61:e6–e75CrossRefGoogle Scholar
  15. 15.
    Hurkmans CW, Knegjens JL, Oei BS, Maas AJ, Uiterwaal GJ, van der Borden AJ, Ploegmakers MM, van Erven L, Dutch Society of Radiotherapy and Oncology (NVRO) (2012) Management of radiation oncology patients with a pacemaker or ICD: a new comprehensive practical guideline in The Netherlands.Dutch Society of Radiotherapy and Oncology (NVRO). Radiat Oncol 7:198CrossRefGoogle Scholar
  16. 16.
    Crossley GH, Poole JE, Rozner MA, Asirvatham SJ, Cheng A, Chung MK, Ferguson TB Jr, Gallagher JD, Gold MR, Hoyt RH, Irefin S, Kusumoto FM, Moorman LP, Thompson A, The Heart Rhythm Society (HRS)/American Society of Anesthesiologists (ASA) (2011) Expert consensus statement on the perioperative management of patients with implantable defibrillators, pacemakers and arrhythmia monitors: facilities and patient management: this document was developed as a joint project with the American Society of Anesthesiologists (ASA), and in collaboration with the American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Heart Rhythm 8:1114–1154CrossRefGoogle Scholar
  17. 17.
    Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20:807–815CrossRefGoogle Scholar
  18. 18.
    Bernardi D, Agati L (2012) Cardiovascular adverse reactions after the administration of recombinant human erythropoietin: light ad shade. Minerva Cardioangiol 60:227–236Google Scholar
  19. 19.
    Ewer MS, Yeh ET (2013) Cancer and the heart, 2nd edn. Peoples Medical Publishing House-USA, ConnecticutGoogle Scholar
  20. 20.
    Yeh ET, Bickford CL (2009) Cardiovascular complication of cancer therapy. J Am Coll Cardiol 53:2231–2247CrossRefGoogle Scholar
  21. 21.
    Timmers HJ, Wieling W, Karemaker JM, Lenders JM (2004) Baroreflex failure: a neglected type of secondary hypertension. Neth J Med 62:151–155PubMedGoogle Scholar
  22. 22.
    Sharabi Y, Dendi R, Homes C, Goldstein DS (2003) Baroreflex failure as a late sequel of neck irradiation. Hypertension 42:110–116CrossRefGoogle Scholar
  23. 23.
    El Menyar AA (2006) Drug-induced myocardial infarction secondary to coronary artery spasm in teenagers and young adults. J Postgrad Med 52:51–56PubMedGoogle Scholar
  24. 24.
    Madeddu C, Deidda M, Piras A, Cadeddu C, Demurtas L, Puzzoni M, Piscopo G, Scartozzi M, Mercuro G (2016) Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy. J Cardiovasc Med (Hagerstown);17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e12-e18Google Scholar
  25. 25.
    Wacker A, Lersch C, Scherpinski U, Reindl L, Seyfarth M (2003) High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients. Oncology 65:108–112CrossRefGoogle Scholar
  26. 26.
    Tsavaris N, Kosmas C, Vadiaka M, Efremidis M, Zinelis A, Beldecos D, Sakelariou D, Koufos C, Stamatelos G (2002) Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy—a survey of 427 patients. Med Sci Monit 8:PI51–PI57PubMedGoogle Scholar
  27. 27.
    Koca D, Salman T, Unek IT, Oztop I, Ellidokuz H, Eren M, Yilmaz U (2011) Clinical and electrocardiography changes in patients treated with capecitabine. Chemotherapy 57:381–387CrossRefGoogle Scholar
  28. 28.
    Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, Karabelis A, Tsavaris N (2008) Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 134:75–82CrossRefGoogle Scholar
  29. 29.
    Jensen SA, Sorensen JB (2006) Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 58:487–493CrossRefGoogle Scholar
  30. 30.
    Nuver J, Smit AJ, van der Meer J, van den Berg MP, van der Graaf WT, Meinardi MT, Sleijfer DT, Hoekstra HJ, van Gessel AI, van Roon AM, Gietema JA (2005) Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 23:9130–9137CrossRefGoogle Scholar
  31. 31.
    Deo SV, Al-Kindi SG, Oliveira GH (2015) Management of advanced heart failure due to cancer therapy: the present role of mechanical circulatory support and cardiac transplantation. Curr Treat Opt Cardiovasc Med 17:1–13CrossRefGoogle Scholar
  32. 32.
    Chow EJ, Chen Y, Kremer LC, Breslow NE, Hudson MM, Armstrong GT, Border WL, Feijen EA, Green DM, Meacham LR, Meeske KA, Mulrooney DA, Ness KK, Oeffinger KC, Sklar CA, Stovall M, van der Pal HJ, Weathers RE, Robison LL, Yasui Y (2015) Individual prediction of heart failure among childhood cancer survivors. J Clin Oncol 33:394–402CrossRefGoogle Scholar
  33. 33.
    Tan TC, Neilan TG, Francis S, Plana JC, Scherrer-Crosbie M (2015) Anthracycline- induced cardiomyopathy in adults. Compr Physiol 5:1517–1540CrossRefGoogle Scholar
  34. 34.
    Gorini S, De Angelis A, Berrino L, Malara N, Rosano G, Ferraro E (2018) Chemotherapeutic drugs and mitochondrial dysfunction: focus on doxorubicin, Trastuzumab, and Sunitinib. Oxidative Med Cell Longev 18:7582730Google Scholar
  35. 35.
    Ewer MS, Ewer SM (2015) Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 12:620CrossRefGoogle Scholar
  36. 36.
    Shelburne N, Adhikari B, Brell J, Davis M, Desvigne-Nickens P, Freedman A, Minasian L, Force T, Remick SC (2014) Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities. J Natl Cancer Inst 10:106Google Scholar
  37. 37.
    Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP (2012) Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60:2504–2512CrossRefGoogle Scholar
  38. 38.
    Oliveira GH, Mukerji S, Hernandez AV, Qattan MY, Banchs J, Durand JB, Iliescu C, Plana JC, Tang WH (2014) Incidence, predictors, and impact on survival of left ventricular systolic dysfunction and recovery in advanced cancer patients. Am J Cardiol 113:1893–1898CrossRefGoogle Scholar
  39. 39.
    Goldhar HA, Yan AT, Ko DT, Earle CC, Tomlinson GA, Trudeau ME, Krahn MD, Krzyzanowska MK, Pal RS, Brezden-Masley C, Gavura S, Lien K, Chan KK (2016) The temporal risk of heart failure associated with adjuvant trastuzumab in breast cancer patients: a population study. J Natl Cancer Inst 108:301CrossRefGoogle Scholar
  40. 40.
    Kalam K, Marwick TH (2013) Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer 49:2900–2909CrossRefGoogle Scholar
  41. 41.
    Lancellotti P, Nkomo VT, Badano LP, Bergler-Klein J, Bogaert J, Davin L, Cosyns B, Coucke P, Dulgheru R, Edvardsen T, Gaemperli O, Galderisi M, Griffin B, Heidenreich PA, Nieman K, Plana JC, Port SC, Scherrer-Crosbie M, Schwartz RG, Sebag IA, Voigt JU, Wann S, Yang PC, European Society of Cardiology Working Groups on Nuclear Cardiology and Cardiac Computed Tomography and Cardiovascular Magnetic Resonance; American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography (2013) Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr 26:1013–1032CrossRefGoogle Scholar
  42. 42.
    Nolan MT, Russell DJ, Marwick TH (2016) Long-term risk of heart failure and myocardial dysfunction after thoracic radiotherapy: a systematic review. Can J Cardiol 32:908–920CrossRefGoogle Scholar
  43. 43.
    Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, Daniel Donovan F, Metzger ML, Arevalo A, Durand JB, Joshi V, Hudson MM, Robison LL, Flamm SD (2012) Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 30:2876–2884CrossRefGoogle Scholar
  44. 44.
    Carver JR, Szalda D, Ky B (2013) Asymptomatic cardiac toxicity in long-term cancer survivors: defining the population and recommendations for surveillance. Semin Oncol 40:229–238CrossRefGoogle Scholar
  45. 45.
    Bijl JM, Roos MM, van Leeuwen-Segarceanu EM, Vos JM, Bos WW, Biesma DH, Post MC (2016) Assessment of valvular disorders in survivors of Hodgkin’s lymphoma treated by mediastinal radiotherapy ± chemotherapy. Am J Cardiol 117:691–696CrossRefGoogle Scholar
  46. 46.
    Virani SA, Dent S, Brezden-Masley C, Clarke B, Davis MK, Jassal DS, Johnson C, Lemieux J, Paterson I, Sebag IA, Simmons C, Sulpher J, Thain K, Thavendiranathan P, Wentzell JR, Wurtele N, Côté MA, Fine NM, Haddad H, Hayley BD, Hopkins S, Joy AA, Rayson D, Stadnick E, Straatman L (2016) Canadian cardiovascular society guidelines for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardiol 32:831–841CrossRefGoogle Scholar
  47. 47.
    Koene RJ, Prizment AE, Blaes A, Konety SH (2016) Shared risk factors in cardiovascular disease and cancer. Circulation 133:1104–1114CrossRefGoogle Scholar
  48. 48.
    Cautela J, Lalevée N, Ammar C, Ederhy S, Peyrol M, Debourdeau P, Serin D, Le Dolley Y, Michel N, Orabona M, Barraud J, Laine M, Bonello L, Paganelli F, Barlési F, Thuny F (2016) Management and research in cancer treatment-related cardiovascular toxicity: challenges and perspectives. Int J Cardiol 224:366–375CrossRefGoogle Scholar
  49. 49.
    Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM (2015) Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131:1981–1988CrossRefGoogle Scholar
  50. 50.
    Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin- converting enzyme inhibition. Circulation 114:2474–2481CrossRefGoogle Scholar
  51. 51.
    Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102:14–25CrossRefGoogle Scholar
  52. 52.
    Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popović ZB, Marwick TH (2013) Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 1:77–84CrossRefGoogle Scholar
  53. 53.
    Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhães A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 15:1063–1093CrossRefGoogle Scholar
  54. 54.
    Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, ESC Scientific Document Group (2016) ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768–2801CrossRefGoogle Scholar
  55. 55.
    Abdel-Qadir H, Amir E, Thavendiranathan P (2016) Prevention, detection, and management of chemotherapy-related cardiac dysfunction. Can J Cardiol 32:891–899CrossRefGoogle Scholar
  56. 56.
    Thavendiranathan P, Poulin F, Lim K-D, Plana JC, Woo A, Marwick TH (2014) Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 63:2751–2768CrossRefGoogle Scholar
  57. 57.
    Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, Cipolla CM (2016) Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin 66:309–325CrossRefGoogle Scholar
  58. 58.
    Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM (2004) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109:2749–2754CrossRefGoogle Scholar
  59. 59.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines (2013) ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol 62:147–239CrossRefGoogle Scholar
  60. 60.
    Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, Rubino M, Veglia F, Fiorentini C, Cipolla CM (2010) Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55:213–220CrossRefGoogle Scholar
  61. 61.
    Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH (2014) Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging 15:324–331CrossRefGoogle Scholar
  62. 62.
    Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH (2017) Cardiovascular complications of Cancer therapy: best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol 70:2536–2551CrossRefGoogle Scholar
  63. 63.
    Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, Baughman KL, Kasper EK (2000) Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342:1077–1084CrossRefGoogle Scholar
  64. 64.
    Shore S, Grau-Sepulveda MV, Bhatt DL, Heidenreich PA, Eapen ZJ, Hernandez AF, Yancy CW, Fonarow GC (2015) Characteristics, treatments, and outcomes of hospitalized heart failure patients stratified by etiologies of cardiomyopathy. JACC Heart Fail 3:906–916CrossRefGoogle Scholar
  65. 65.
    Rickard J, Kumbhani DJ, Baranowski B, Martin DO, Tang WH, Wilkoff BL (2010) Usefulness of cardiac resynchronization therapy in patients with Adriamycin- induced cardiomyopathy. Am J Cardiol 105:522–526CrossRefGoogle Scholar
  66. 66.
    Ajijola OA, Nandigam KV, Chabner BA, Orencole M, Dec GW, Ruskin JN, Singh JP (2008) Usefulness of cardiac resynchronization therapy in the management of doxorubicin-induced cardiomyopathy. Am J Cardiol 101:1371–1372CrossRefGoogle Scholar
  67. 67.
    Reulen RC, Winter DL, Frobisher C, Lancashire ER, Stiller CA, Jenney ME, Skinner R, Stevens MC, Hawkins MM, British Childhood Cancer Survivor Study Steering Group (2010) Long-term cause-specific mortality among survivors of childhood cancer. JAMA 304:172CrossRefGoogle Scholar
  68. 68.
    Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, Valero V (2007) Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 25:4952–4960CrossRefGoogle Scholar
  69. 69.
    Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE (2003) Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 21:3431–3439CrossRefGoogle Scholar
  70. 70.
    Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK, Douglas PS, Bhatia S, Chao C (2016) Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol 34:1122–1130CrossRefGoogle Scholar
  71. 71.
    Fidler MM, Reulen RC, Henson K, Kelly J, Cutter D, Levitt GA, Frobisher C, Winter DL, Hawkins MM (2017) Population-based long-term cardiac-specific mortality among 34 489 five-year survivors of childhood Cancer in Great Britain.; British childhood Cancer survivor study (BCCSS) steering group. Circulation 135:951–963CrossRefGoogle Scholar
  72. 72.
    Wouters KA, Kremer LCM, Miller TL, Herman EH, Lipshultz SE (2005) Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 131:561–578CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Peggy M. Kostakou
    • 1
    Email author
  • Nikos T. Kouris
    • 1
  • Vassilios S. Kostopoulos
    • 1
  • Dimitrios S. Damaskos
    • 1
  • Christoforos D. Olympios
    • 1
  1. 1.Cardiology DepartmentGeneral Hospital of Elefsina ‘Thriassio’AthensGreece

Personalised recommendations